On the recordMarch 23, 2016
I am. The SPEAKER pro tempore. The Clerk will report the motion to recommit. The Clerk read as follows: Mr. Doggett moves to recommit the bill (H.R. 2745) to the Committee on the Judiciary, with instructions to report the bill back to the House forthwith with the following amendment: At the end of the bill, add the following: SEC. 5. PROTECTING CONSUMERS AGAINST HIGH PRESCRIPTION DRUG COSTS. (a) This Act and the amendments made by this Act shall not apply to mergers that would unreasonably increase the costs of pharmaceutical drugs. (b) The Clayton Act (15 U.S.C.12 et seq.) and Federal Trade Commission Act (15 U.S.C. 45 et seq.) as in effect immediately before the date of the enactment of this Act shall apply to mergers that would unreasonably increase the costs of pharmaceutical drugs. The SPEAKER pro tempore. Pursuant to the rule, the gentleman from Texas is recognized for 5 minutes in support of his motion.
